|Home | About | Journals | Submit | Contact Us | Français|
The development of sedative/hypnotic molecules has been empiric rather than rational. The empiric approach has produced clinically useful drugs but for no drug is the mechanism of action completely understood. All available sedative/hypnotic medications have unwanted side effects and none of these medications creates a sleep architecture that is identical to the architecture of naturally occurring sleep. This chapter reviews recent advances in research aiming to elucidate the neurochemical mechanisms regulating sleep and wakefulness. One promise of rational drug design is that understanding the mechanisms of sedative/hypnotic action will significantly enhance drug safety and efficacy.
Sleep states are comprised of a constellation of physiological and behavioral traits, and the mechanisms by which sedative/hypnotic medications alter these traits remain unclear. Drugs that enhance states of sleep also alter autonomic physiology, behavior, cognition, and affect. The complexities of brain neurochemistry and the extensive neural circuits regulating levels of behavioral arousal contribute to the present inability to understand exactly how sedative/hypnotics promote sleep. An additional complexity is that many sedative/hypnotic drugs have behavioral state-specific actions. For example, some sedative/hypnotic drugs promote the non-rapid eye movement (NREM) phase of sleep at the expense of decreasing the rapid eye movement (REM) phase of sleep. In spite of the foregoing limitations, there has been progress in developing sleep medications that maximize desired actions such as rapid sleep onset, minimal next day effect, low or no abuse potential, and creation of a drug-induced state that is indistinguishable from physiological sleep. To date, however, no sedative/hypnotic produces all of these desired effects.
Rational drug design is an approach that has been successful in the development of antibiotic medications. Rational drug development of sedative/hypnotic medications is an approach based on understanding the receptor-binding properties of a molecule and how a molecule alters ligand binding, neurotransmitter synthesis, release, reuptake, and degradation. All of the foregoing cellular mechanisms can then be interpreted in the context of the overall drug effect. For sedative/hypnotic medications the desired action is, of course, promoting a safe and restorative sleep-like state. This chapter and Figure 1 provide an overview of neurotransmitters and brain regions currently known to modulate states of sleep and wakefulness. This overview of sleep neuropharmacology can be read as a précis of a recent chapter1 and interested readers are referred elsewhere for detailed reviews on sleep.2–8
GABA is the major inhibitory neurotransmitter in the brain, and activation of GABAA receptors causes neuronal inhibition by increasing chloride ion conductance. Because of their powerful inhibitory effects, GABAA receptors are the targets of most sedative/hypnotic and general anesthetic drugs. GABAA receptors exist as multiple subtypes (reviewed in9) and these subtypes are differentially located throughout the brain (reviewed in10). The differences in clinical effects caused by various benzodiazepine (e.g., diazepam) and non-benzodiazepine (e.g., eszopiclone) sedative/hypnotics are attributed to the relative selectivity of these drugs for different GABAA receptor subtypes.10 The complexity imparted by the numerous GABAA receptor subtypes is humbling. Although there is detailed knowledge about the many subunit isoforms that comprise GABAA receptor subtypes,9 information is lacking about which of the many possible subtypes actually are expressed in specific brain regions,11–13 and which subtypes are localized synaptically verses extrasynaptically.14 Extrasynaptically localized GABAA receptors possess a delta subunit and have particular relevance for sleep medicine.15, 16
A better understanding of the in vivo characteristics and anatomical localization of GABAA receptor subtypes will contribute to rationale drug development. The preclinical studies described in this section illustrate the complexity of the problem and provide examples of how the effects of GABAergic drugs on behavior vary as a function of brain region. For example, although systemic administration of GABAmimetic drugs promotes sleep, sedation, or general anesthesia, enhancing GABAergic transmission within the pontine reticular formation actually increases wakefulness and decreases sleep. The pontine reticular formation is part of the ascending reticular activating system and contributes to the generation of REM sleep. Direct administration into the pontine reticular formation of drugs that increase GABAergic transmission increases wakefulness and inhibits sleep.17–20 Similarly, pharmacologically increasing the concentration of endogenous GABA within the pontine reticular formation increases the time required for isoflurane to induce general anesthesia.21 Consistent with this finding are data showing that endogenous GABA levels in the pontine reticular formation are greater during wakefulness than during REM sleep22 or during the loss of wakefulness caused by isoflurane.21 Inhibiting GABAergic signaling at GABAA receptors within the pontine reticular formation causes an increase in REM sleep and a decrease in wakefulness 18, 19, 23, 24. Likewise, decreasing extracellular GABA levels in the pontine reticular formation of rat decreases wakefulness and increases sleep,20 and shortens the time required for isoflurane to induce loss of consciousness.21 Furthermore, blocking GABAA receptors in the pontine reticular formation increases time needed to regain wakefulness after isoflurane anesthesia.18 Considered together, these data demonstrate a wakefulness-promoting role for GABA in the pontine reticular formation.
In brain regions containing neurons that promote wakefulness, GABAergic inhibition has been shown to cause an increase in sleep. These brain regions include the dorsal raphé nucleus (Fig. 1; DRN), tuberomamillary nucleus of the posterior hypothalamus (Fig. 1; TMN), medial preoptic area (Fig. 1; MPO), and ventrolateral periaqueductal gray25 (for reviews see7, 26, 27).
Acetylcholine is distinguished as being the first identified neurotransmitter. Although the first neurochemical theory of sleep28 correctly posited that acetylcholine plays a primary role in generating the brain-activated states of wakefulness and REM sleep, cholinergic drugs are not part of the standard pharmacological armamentarium of sleep disorders medicine. Nonetheless, understanding the mechanisms by which cholinergic neurotransmission generates and maintains REM sleep is crucial, because acetylcholine interacts with other transmitter systems that are targets of sleep pharmacotherapy (e.g., GABAergic and monoaminergic). Much of the research on the regulation of sleep by acetylcholine has focused on transmission mediated by muscarinic cholinergic receptors. Five subtypes (M1–M5) of the muscarinic receptor have been identified,29 and the M2 subtype plays a key role in the generation of REM sleep.30
Cholinergic signaling originating from the laterodorsal tegmental and pedunculopontine tegmental nuclei (LDT/PPT) and the basal forebrain (see Fig. 1) promotes the cortically activated states of wakefulness and REM sleep (reviewed in31). LDT/PPT neurons can be divided into two populations based on discharge pattern. One population discharges maximally during wakefulness and REM sleep (referred to as Wake-On/REM-On) and another population fires only during wakefulness (Wake-On/REM-Off) (reviewed in2). This finding helps explain how acetylcholine can promote both wakefulness and REM sleep. LDT/PPT neurons project to numerous wakefulness-promoting brain regions.2 Cholinergic terminals in the pontine reticular formation arise from the LDT/PPT,2 and muscarinic receptors are present in the pontine reticular formation.30, 32, 33 Many studies have administered cholinomimetics to the pontine reticular formation and have demonstrated that cholinergic transmission in the pontine reticular formation induces REM sleep (reviewed in2, 31). Electrically stimulating the LDT/PPT increases acetylcholine release in the pontine reticular formation34 and increases REM sleep.35 The release of endogenous acetylcholine in the pontine reticular formation is significantly greater during REM sleep than during wakefulness or NREM sleep.36–38 Taken together, these data demonstrate that cholinergic projections from the LDT/PPT to the pontine reticular formation promote REM sleep.
Recent in vivo data obtained from normal rats demonstrate that the sedative/hypnotics zolpidem, diazepam, and eszopiclone differentially alter acetylcholine release in the pontine reticular formation.39 Intravenous administration of eszopiclone prevented the REM phase of sleep, increased EEG delta power, and decreased acetylcholine release in rat pontine reticular formation.39 These data provide the first functional evidence for a heterogeneous distribution of GABAA receptor subtypes within the pontine reticular formation. The different effects of GABAA receptor agonists on sleep have been attributed to brain region-specific distributions of GABAA receptors and differences in sedative/hypnotic affinities for GABAA receptor subtypes.40 These preclinical data can be contrasted with human psychopharmacology where there has been no study convincingly demonstrating differential GABAA subtype binding among benzodiazepine and non-benzodiazepine sleeping medications.40 To date, the non-benzodiazepine, benzodiazepine-receptor agonist eszopiclone remains the only sleeping medication for which the long-term (6 months) effects have been characterized.41, 42
Cholinergic neurons originating in the basal forebrain project throughout the entire cerebral cortex (reviewed in43). Acetylcholine release in the basal forebrain is highest during REM sleep, lower during quiet wakefulness, and lowest during NREM sleep.44 Cortical acetylcholine release is increased during wakefulness43, 45, 46 and REM sleep45 as compared to NREM sleep. These support the interpretation that cholinergic transmission from the basal forebrain promotes cortical activation during wakefulness and REM sleep.
Adenosine is a breakdown product of adenosine triphosphate (ATP). Increases in endogenous adenosine levels in a specific brain region during a period of prolonged wakefulness indicate that the region has been metabolically active. Direct biochemical measures show that ATP levels increase during sleep in areas of the brain that are most active during wakefulness.47 This finding provides direct support for the hypothesis that sleep serves a restorative function.48
Four subtypes of adenosine receptors, A1, A2A, A2B, and A3, have been identified and are distributed widely throughout the brain. Adenosine A1 and A2A receptors are antagonized by caffeine and the idea that adenosine promotes sleep is supported by the ubiquitous consumption of caffeine to maintain wakefulness and enhance alertness. In humans, oral administration of caffeine prior to nocturnal sleep increases sleep latency and reduces sleep efficiency.49 Furthermore, morning caffeine ingestion has been shown to decrease sleep efficiency and overall sleep during the subsequent night.50 No adenosine agonists are presently available to promote sleep. Adenosine, however, is relevant for sleep medicine, as insomnia can be caused by consumption of caffeine or by the respiratory stimulant theophylline. Interestingly, adenosine can have analgesic effects and this action shows promise for clinical use.51
Adenosinergic transmission in brain regions that regulate sleep and wakefulness has been extensively investigated (reviewed in2, 52–54). Activating adenosine A1 receptors causes neuronal inhibition, and A1 is the most abundant adenosine receptor subtype in brain. This section highlights selected studies supporting the interpretation that adenosine promotes sleep, at least in part, by inhibiting neurons in several key wakefulness-promoting brain areas.
Prolonged wakefulness increases adenosine levels selectively in the basal forebrain (Fig. 1; BF) and cortex,55 and increases adenosine A1 receptor binding in human56 and rat57 brain. Pharmacologically increasing adenosine levels in the basal forebrain58 or administering adenosine A1 receptor agonists to the basal forebrain54 causes an increase in sleep. Inactivating adenosine A1 receptors in the basal forebrain decreases EEG delta power and NREM sleep time,59 and immunohistochemical studies reveal that the basal forebrain contains A1 receptors, but not A2A receptors.60 Cholinergic neurons in the basal forebrain project to the cortex and contribute to the EEG activation characteristic of wakefulness and REM sleep. Adenosine directly inhibits cholinergic neurons in the basal forebrain by activating A1 receptors.61 Adenosine indirectly inhibits wakefulness-promoting hypocretin (orexin)-containing neurons in the lateral hypothalamus (Fig. 1; LH) by activating A1 receptors.62 Blocking adenosine A1 receptors in the lateral hypothalamus causes an increase in wakefulness and a decrease in sleep.63 Histaminergic neurons in the tuberomammillary nucleus (Fig. 1; TMN) express adenosine A1 receptors, and activating those receptors increases NREM sleep.64 These complementary data suggest that adenosine promotes sleep by inhibiting wakefulness-promoting neurons localized to the basal forebrain, lateral hypothalamus, and tuberomammillary nucleus.
Adenosine also exerts sleep-promoting effects by actions at the level of the prefrontal cortex (Fig. 1; PFC) and the pontine reticular formation (Fig. 1; PnO, PnC). In vivo microdialysis experiments in mouse65 have shown that adenosine acting at A1 receptors in the prefrontal cortex inhibits traits that characterize wakefulness (including acetylcholine release in the prefrontal cortex and activation of the EEG), as well as the state of wakefulness. Activation of adenosine A1 receptors in the prefrontal cortex also causes a decrease in the release of acetylcholine in the pontine reticular formation. These findings demonstrate that in the prefrontal cortex, adenosine A1 receptors mediate a descending inhibition of wakefulness-promoting systems. Within the pontine reticular formation, activation of adenosine A2A receptors increases time needed to recover from general anesthesia,66 increases acetylcholine release,66, 67 and increases the amount of time spent in NREM sleep67 and REM sleep.67, 68 The increase in REM sleep may be a result of the A2A-mediated increase in acetylcholine release, because coadministration of a muscarinic receptor antagonist with the A2A agonist blocks the REM sleep increase.68 Studies examining the effects on sleep of adenosine receptor antagonists are required in order to conclude that endogenous adenosine within the pontine reticular formation modulates sleep. The finding that clinically used opioids, such as morphine and fentanyl, decrease adenosine levels in the pontine reticular formation69 and disrupt REM sleep (reviewed in70) suggests the possibility that adenosinergic transmission within the pontine reticular formation participates in REM sleep generation.
The monoamines have long been known to promote wakefulness. Serotonin (5-hydroxytryptamine; 5HT)-containing neurons of the dorsal raphé nucleus (Fig. 1; DRN), norepinephrine-containing neurons of the locus coeruleus (Fig. 1; LC), and histamine-containing neurons of the tuberomammillary nucleus (Fig. 1; TMN) discharge at their fastest rates during wakefulness, slow their firing in NREM sleep, cease discharging prior to and during REM sleep, and resume firing prior to the onset of wakefulness (reviewed in2). Dopaminergic neurons, by contrast, do not show major changes in firing rates across the sleep-wakefulness cycle.
Serotonin release in the dorsal raphé nucleus71 and preoptic area72 of rat is highest during wakefulness. Furthermore, electrical stimulation of the dorsal raphé nucleus increases wakefulness.73 Serotonin receptors are divided into seven families (5HT1–5HT7).74 Systemic administration of agonists for 5HT1A, 5HT1B, 5HT2A/2C or 5HT3 receptors causes an increase in wakefulness and a decrease in sleep (reviewed in75). Local administration of a 5HT1A receptor agonist to the dorsal raphé nucleus increases wakefulness in rat76 but increases REM sleep in cat.77 Microinjection of a 5HT2A/2C receptor agonist into rat dorsal raphé nucleus also decreases REM sleep with no significant effect on wakefulness.78 These incongruent findings may be due to species differences, or may indicate that in addition to promoting wakefulness, serotonin plays a permissive role in the generation of REM sleep. Systemic administration of antagonists for the 5HT2A receptor or the 5HT6 receptor to rat decreases wakefulness, increases NREM sleep, and has no effect on REM sleep.79 These data are consistent with the view that serotonin is wakefulness-promoting. Genetically modified mice also have been used to explore the role of serotonin in sleep and wakefulness. Mice lacking the genes for the 5HT1A80 or 5HT1B81 receptor showed an increase in REM sleep. Administration of a 5HT1A80, 82, a 5HT1B81, or a 5HT2A/2C83 receptor agonist decreased REM sleep in rodent and human. These data indicate that serotonin acting at 5HT1A, 5HT1B, and 5HT2A/2C receptors plays a role in suppressing REM sleep. The forgoing data underlie the fact that insomnia can be secondary to the use of selective serotonin reuptake inhibitors (SSRI) or serotonin, norepinephrine reuptake inhibitors (SNRI).
Noradrenergic cells of the locus coeruleus inhibit REM sleep, promote wakefulness, and project to a variety of other arousal-regulating brain regions (Fig. 1) including the hypothalamus, thalamus, basal forebrain, and cortex (reviewed in84). Noradrenergic receptors include α 1-, α 2-, and β-adrenergic subtypes.85 Administration of noradrenaline or α- and β-receptor agonists to the medial septal area86, 87 or the medial preoptic area88, 89 increases wakefulness. Stimulation of locus coeruleus neurons increases noradrenaline in the prefrontal cortex of anesthetized rat,90, 91 and contributes to cortical activation. These data are consistent with the view that noradrenaline promotes wakefulness. However, bilateral microinjection of an α 1-antagonist (prazosin), an α 2-agonist (clonidine), or a β-antagonist (propranolol) into the pedunculopontine tegmental nucleus increases REM sleep with little to no effect on NREM sleep or wakefulness.92 The arousal-regulating effects of noradrenaline are brain-region specific. The treatment of hypertension with blockers of α- and/or β-adrenergic receptors can disrupt normal sleep.
Histaminergic cell bodies, which are located in the tuberomamillary nucleus of the posterior hypothalamus have diffuse projections throughout the brain (reviewed in93). Data from posterior hypothalamic lesion studies and from single unit recordings indicate that the tuberomamillary nucleus promotes wakefulness.93 Three histaminergic receptors, denoted H1, H2, and H3, are present in the brain (for review see94). First generation H1 receptor antagonists, such as diphenhydramine, cause drowsiness (sedation) and impaired performance in humans95 and rats.96 Newer antagonists that are relatively selective for the H1 histamine receptor, such as the potent antagonist doxepin, improve subjective and objective measures of sleep in insomnia patients without causing sedation or psychomotor impairments the next day.97 Systemic administration of the H1 receptor antagonists mepyramine98 and cyproheptadine99 caused a significant increase in NREM sleep in cat and rat, respectively. Decreasing brain histamine levels by inhibiting synthesis significantly decreases wakefulness and increases NREM sleep in rat100, 101 and cat.98 These data suggest that histaminergic signaling via the H1 receptor promotes wakefulness. New therapies for sleep disorders and for maintaining vigilance include H3 receptor antagonists and inverse agonists.102–104
Stimulants such as amphetamine, cocaine, and methylphenidate increase wakefulness and counter hypersomnia by increasing levels of endogenous dopamine (reviewed in105). In vivo imaging studies suggest that sleep deprivation increases dopamine levels in human brain.106 The cell bodies of dopaminergic neurons that regulate arousal reside in the ventral tegmental area (Fig. 1; VTA) and the substantia nigra pars compacta.75 These dopaminergic neurons project to the dorsal raphé nucleus, basal forebrain, locus coeruleus, thalamus, and LDT (reviewed in107). There are also dopaminergic neurons in the ventrolateral periaqueductal gray that are active during wakefuless and have reciprocal connections with sleep-regulating brain areas.108
Five dopaminergic receptors have been cloned (D1–D5). Dopaminergic neurons of the substantia nigra and ventral tegmental area do not change firing rates as a function of states of sleep and wakefulness(reviewed in2). Dopamine does promote wakefulness and dopamine-transporter-knockout mice display increased wakefulness and decreased NREM sleep compared to controls.109 Systemic administration of D1 receptor agonists or antagonists causes an increase or decrease, respectively, in wakefulness.110 Intracerebroventricular administration of a D1 or D2 receptor agonist to rat increases wakefulness.111 Systemic administration of a D2 receptor agonist causes biphasic effects with low doses decreasing wakefulness and high doses increasing wakefulness.112, 113 Systemic administration of D-amphetamine to rat increases wakefulness and decreases NREM sleep and REM sleep.114 The mechanisms by which modafinil counters excessive daytime sleepiness remain to be specified. There is evidence that modafinil enhances synaptic release of dopamine and norepinephrine.115
Glutamate is the main excitatory neurotransmitter in the brain and acts at α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate, and N-methyl-D-aspartate (NMDA) ionotropic receptors. Surprisingly, little is known about glutamatergic regulation of sleep and wakefulness. Sleep state-dependent changes in levels of endogenous glutamate change differentially across the brain (see Table 8 of116). For example, glutamate levels in some areas of rat cortex show increases in concentration during wakefulness and REM sleep, and decreases during NREM sleep.117 Microinjection and electrophysiological studies provide evidence that glutamate acts within the laterodorsal tegmental nucleus and pedunculopontine tegmental nucleus118–120 (Fig. 1; PPT), the pontine reticular formation121–123 (Fig. 1; PnO, PnC), and medial portions of the medullary reticular formation122, 124 to modulate traits and states of arousal. Glutamatergic neurons are present in rat pontine reticular formation125 and neurons in the pontine reticular formation are capable of synthesizing glutamate for use as a neurotransmitter.126 Glutamate elicits excitatory responses from pontine reticular formation neurons,127, 128 and glutamatergic and cholinergic transmission in the pontine reticular formation interact synergistically to potentiate catalepsy.129 Given individually, agonists for AMPA, kainate, and NMDA receptors evoke excitatory responses from pontine reticular formation neurons.121 Dialysis delivery of the NMDA receptor antagonists ketamine or MK-801 to cat pontine reticular formation decreases acetylcholine release in the pontine reticular formation and disrupts breathing.38
Many peptides are known to modulate sleep (reviewed in130). The present chapter focuses on hypocretin (orexin), leptin, and ghrelin because of their relevance for sleep disorders medicine.
Numerous lines of evidence support a role for hypocretin-1 and -2 (also called orexin A and B) in the maintenance of wakefulness. The cell bodies of hypocretin-producing neurons are localized to the dorsolateral hypothalamus131, 132 and send projections to all the major brain regions that regulate arousal.133, 134 Hypocretinergic neurons discharge with the highest frequency during active wakefulness and show almost no discharge activity during sleep.135, 136 Hypocretin-1 levels in the hypothalamus of cat are greater during wakefulness and REM sleep than during NREM sleep.137 Dogs displaying a narcoleptic phenotype have a mutation of the hypocretin receptor-2 gene,138 and hypocretin mRNA and peptide levels are greatly reduced in human narcoleptic patients.139, 140 Patients presenting with narcolepsy-cataplexy also have greatly reduced levels of hypocretin in their cerebrospinal fluid compared to controls.141 Preclinical studies have demonstrated that selective lesions of hypocretin-containing neurons142, 143 or genetic removal of the peptide144 result in a narcoleptic phenotype. By what mechanisms might hypocretin enhance wakefulness?
Two receptors for the hypocretin peptides have been identified. Hypocretin-1 and -2 receptors have been localized to the LDT/PPT, pontine reticular formation, dorsal raphé nucleus, and locus coeruleus.145–149 Electrophysiological studies demonstrate that hypocretin-1 and/or hypocretin-2 excite neurons in these same brain regions.150–158 Hypocretin-1 and -2 also excite tuberomamillary neurons159, 160 and cholinergic neurons of the basal forebrain.161
Intracerebroventricular administration of hypocretin-1 increases wakefulness and decreases NREM sleep and REM sleep in rat.162, 163 When administered into the lateral preoptic area,164 the LDT,165 pontine reticular formation,20, 166 or basal forebrain,167, 168 hypocretin-1 causes an increase in wakefulness. In cat, microinjection of hypocretin-1 into the pontine reticular formation increases REM sleep if delivered during NREM sleep,152 but suppresses REM sleep if delivered during wakefulness.166 The wakefulness-promoting effect of hypocretin in the pontine reticular formation is further supported by evidence that delivery of antisense oligionucleotides against the hypocretin-2 receptor to the pontine reticular formation of rat enhance REM sleep and induce cataplexy.169
Measuring the effect of hypocretin-1 on the release of other arousal-regulating transmitters may provide insight into how hypocretin-1 promotes wakefulness. Microinjection of hypocretin-1 into the basal forebrain of rat increases cortical acetylcholine release.170 Intracerebroventricular delivery of hypocretin-increases histamine in rodent frontal cortex171 and anterior hypothalamus.172 Microinjection of hypocretin-1 into the ventricles or the ventral tegmental area increases dopamine release in rat prefrontal cortex.163 Hypocretin-1 delivered to rat dorsal raphé nucleus increases serotonin release in the dorsal raphé nucleus,173 and dialysis delivery of hypocretin-1 to rat pontine reticular formation increases acetylcholine release174 and GABA levels20 in the pontine reticular formation. The increase in wakefulness produced by microinjecting hypocretin-1 into the pontine reticular formation is prevented by blocking GABAA receptors.175 This finding suggests that hypocretin may increase wakefulness, in part, by increasing GABA levels in the pontine reticular formation. Considered together, these data support the classification of hypocretin-1 as a wakefulness-promoting neuropeptide.
An alternative hypothesis is that a primary function of hypocretin is to enhance activity in motor systems and the increase in wakefulness is secondary. This hypothesis is supported by data showing that hypocretin-1 concentrations in the cerebrospinal fluid are significantly greater during active wakefulness with movement than during quiet wakefulness with no movement.137 Hypocretinergic neurons also have very low firing rates during quiet wakefulness (without movement) compared to active wakefulness.135, 136 Oral administration of the hypocretin-1 and -2 receptor antagonist ACT-078573 increases NREM sleep and REM sleep in rat, dog, and human,176 suggesting a direct, wakefulness-promoting effect of endogenous hypocretin.
Due to the ongoing epidemic of obesity and the association between metabolic syndrome and sleep disorders, many studies aim to understand the sleep-related roles of leptin and ghrelin. Decreased levels of leptin (a hormone that suppresses appetite) and increased levels of ghrelin (a hormone that stimulates appetite) are associated with short sleep duration in humans.177, 178 The sleep of ob/ob mice (obese mice with reduced levels of leptin) is characterized by an increase in number of arousals and a decrease in the duration of sleep bouts compared to wild type controls.179 The ob/ob mice also have an impaired response to the cholinergic enhancement of REM sleep.180 Similarly, db/db mice (which are also obese but are resistant to leptin) have significant alterations in sleep architecture compared to wild type control mice that include, but are not limited to, increases in NREM sleep and REM sleep during the dark phase and decreases in wakefulness and NREM sleep bout duration.181 Local administration of ghrelin into rat lateral hypothalamus, medial preoptic area, or paraventricular nucleus increases wakefulness, decreases NREM sleep, and increases food intake.182 Together, these findings suggest that leptin and ghrelin, hormones that are important for appetite regulation, significantly influence sleep and are significantly modulated by sleep.
Opioids are the major class of drugs used to treat acute and chronic pain, and one side effect of opioids is sleep disruption. Sleep disruption, in turn, exacerbates pain183, 184 and increases the dose of opioids required for successful pain management (reviewed in69, 70). Clinically relevant doses of opioids given to otherwise healthy humans disrupt sleep (reviewed in185). For example, a single intravenous infusion of morphine in healthy volunteers decreases stages 3 and 4 NREM sleep, decreases REM sleep, and increases stage 2 NREM sleep.186 A nighttime dose of morphine or methadone also decreases stages 3 and 4 NREM sleep while increasing stage 2 NREM sleep.187 Constant infusion of analgesic doses of remifentanil overnight decreases REM sleep in healthy volunteers.188 The cycle of opioid-induced sleep disruption leading to increased pain and increased opioid requirement is recognized as a significant clinical problem that must be addressed at the mechanistic level.189
Opioid-induced disruption of REM sleep is mediated, at least in part, by decreasing acetylcholine release in the pontine reticular formation.70 Opioids also decrease adenosine levels in the basal forebrain and in the pontine reticular formation,69 two brain regions where adenosine has sleep-promoting effects. Local administration of morphine into the pontine reticular formation of cat190 or rat191 increases wakefulness and decreases REM sleep.
This selective overview was completed during the summer of 2010, a date also marking the 20th anniversary of the human genome project. The stunning successes – and unmet hopes – of genomic approaches to medicine were highlighted in the June 12th and 14th issues of The New York Times.192, 193 These two articles offer a sobering reminder that taking a molecule from pre-clinical discovery to commercially available drug typically requires 15 or more years. This time interval is without any mandate to understand the mechanisms of drug action. As a former director of research and development at Wyeth noted193 “Genomics did not speed up drug development. It gave us more rapid access to new molecular targets.” Potential molecular targets can be rapidly interrogated with high throughput screening programs that use a cell line transfected to contain a reporter construct. But identifying potential molecular targets leaves unanswered the question of whether the candidate targets will be druggable in vivo. This complexity is exemplified by sedative/hypnotic medications commonly used in sleep medicine. GABAA receptors are drug targets that promotes a sleep-like state by unknown actions40 when they are activated in some brain regions, yet GABAA receptors enhance wakefulness when activated selectively in the posterior hypothalamus194 or pontine reticular formation.18, 19, 21 As busy as Fig. 1 may seem, it barely hints at the complexity of data that must be logically integrated if we are to derive a coherent model of the endogenous neurochemical processes that regulate states of sleep and wakefulness.
Recent progress in understanding the basic neuropharmacology of sleep can be appreciated by comparing the 1990 and the 2005 editions of Brain Control of Wakefulness and Sleep.2 The incorporation of basic neuropharmacology into sleep disorders medicine is readily apparent by comparing the first and most recent editions of Principles and Practice of Sleep Medicine.195 Future progress is most likely to come from a systems biology approach that seeks to integrate genomic, cellular, network, and behavioral levels of analysis.196 The focus on sleep medications in the Clinics of North America series demonstrates the cross-cutting relevance of sleep for the practice of medicine. The pressing clinical problem of sleep disorders medicine will continue to stimulate advances in understanding the neurochemical regulation of sleep.
Disclosure Statement: This work supported by National Institutes of Health grants: HL40881, HL65272, HL57120, MH45361, and the Department of Anesthesiology. We thank Mary A. Norat, and Sarah L. Watson for critical comments on this chapter. This work was not an industry-supported study and the authors have no financial conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.